Unknown PHASE2 INTERVENTIONAL 2-arm NCT02067013

Analysis of Aqueous and Vitreous Humor (ARK)

Analysis of Vitreous and Aqueous Humor for Ocular Growth Factors, Cytokines, Chemokines, and Ranibizumab Pharmacokinetics Associated With Various Retinal Disease

Sponsor: California Retina Consultants

Conditions Macular Degeneration Macular Hole Neovascular Glaucoma Proliferative Diabetic Retinopathy

Interventions No Ranibizumab Ranibizumab

Updated 7 times since 2017 Last updated: Feb 28, 2017 Started: Jul 31, 2015 Primary completion: Jul 31, 2017 Completion: Jul 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Macular Degeneration and Macular Hole, this trial is ongoing. The trial is conducted by California Retina Consultants and has accumulated 7 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Mar 2019 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jun 2018 — Mar 2019 [monthly]

Recruiting PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2

First recorded

Jul 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

California Retina Consultants

Data source: California Retina Consultants

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Santa Barbara, United States